<DOC>
	<DOCNO>NCT01133912</DOCNO>
	<brief_summary>Primary objective : 1 . To evaluate recommend dose combination paclitaxel , gemcitabine , lapatinib ( Tykerb® ) ( PGT ) preoperative chemotherapy patient HER2 positive operable breast cancer Secondary objective : 1 . To evaluate maximum tolerate dose ( MTD ) dose-limiting toxicity ( DLT ) PGT 2 . To determine safety profile 3 . To assess pCR primary tumor axillary LN 4 . To evaluate clinical response rate , disease free survival ( DFS ) , overall survival ( OS ) 5 . To assess breast conserve rate preoperative PGT</brief_summary>
	<brief_title>Preoperative Chemotherapy With Paclitaxel , Gemcitabine , Lapatinib ( Tykerb® ) ( PGT )</brief_title>
	<detailed_description>Unlike adjuvant chemotherapy , primary ( preoperative ) chemotherapy shrink tumor allow patient become candidate conservative surgery avoid mastectomy . It also vivo chemosensitivity test result predictive marker clinical outcome . Paclitaxel highly active antitumor agent promote microtubule assembly bind tubulin inhibit depolymerization . Paclitaxel show effective agent treatment breast cancer . Gemcitabine cytosine arabinoside prodrug analog show response rate 15 % 46 % single agent low toxicity . The combination gemcitabine paclitaxel valuable different mechanism action drug non-overlapping toxicity . Phase II study paclitaxel plus gemcitabine anthracycline-pretreated metastatic breast cancer show good tolerance encouraging response rate ( 40 % -55 % ) . Paclitaxel plus gemcitabine combination show overall survival benefit compare paclitaxel alone patient metastatic breast cancer interim overall survival report . A phase II study preoperative paclitaxel gemcitabine stage II/III show 18 % pCR rate NCC ( ASCO 2007 abstract # 11080 ) In HER2 positive breast cancer , HER2 target therapy trastuzumab lapatinib show much improve clinical response palliative setting . It also show add trastuzumab sequential paclitaxel FEC chemotherapy significantly increase pCR ( 25 % vs 66.7 % ) preoperative set HER2 positive disease . Recently , paclitaxel , gemcitabine , trastuzumab combination ( PGH ) 6 cycle patient HER2 positive node positive operable breast cancer observe strikingly high pCR rate tumor LN interim analysis multicenter phase II preoperative study Korea ( 28 47 ( 61 % ) ) . Lapatinib ( Tykerb® ) , dual tyrosine kinase inhibitor ErbB1 HER2 signal pathway show inhibit growth HER2 overexpressing breast cancer cell respond trastuzumab long-term conditioning . We examine hypothesis paclitaxel , gemcitabine , lapatinib ( Tykerb® ) ( PGT ) combination could improve pathological complete response rate HER2 positive breast cancer apply preoperative chemotherapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Histologically confirm newly diagnose operable breast cancer Documented HER2 positive disease : 3+ overexpression IHC HER2 gene amplification FISH ECOG performance status 02 Age ≥ 18 year Clinical stage II III operable breast cancer Axillary node positivity determine cytology No prior hormonal , chemotherapy , radiotherapy allow No breast operation biopsy make diagnosis allow Negative urine pregnancy test within 7 day prior registration premenopausal patient Adequate hematopoietic function : Absolute granulocyte count ≥1,500/mm3 , platelet ≥100,000/mm3 , hemoglobin ≥10g/mm3 Adequate hepatic function : total bilirubin ≤1.5mg/dL , AST/ALT ≤2 x UNL , alkaline phosphatase ≤2 x UNL Adequate renal function : Serum creatinine ≤1.5mg/dL Adequate cardiac function : 1 . Normal nonspecific EKG take within 1 month enrollment 2 . LVEF ≥50 % MUGA echocardiogram take within 4 week enrollment Ability understand comply protocol study period Patients sign write informed consent study entry Pregnant lactate woman Patients receive hormonal , chemotherapy radiotherapy breast cancer Patients bilateral breast cancer Patients underwent surgery breast cancer Patients nodenegative stage IIA ( T2N0 ) breast cancer Patients history cancer situ uterine cervix cancer nonmelanotic skin cancer Patients GI tract disease result inability take oral medication , malabsorption syndrome , requirement IV alimentation , prior surgical procedure affect absorption , uncontrolled GI disease ( e.g. , Crohn 's disease , ulcerative colitis )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Patients HER2 Positive Operable Breast Cancer</keyword>
</DOC>